Over 22% of people residing in war-torn or conflict-stricken areas of the world have at least one mental disorder, including depression, anxiety, post-traumatic stress disorder, bipolar disorder, and schizophrenia, according to data from the World Health Organization. (The Lancet)
The investigational schizophrenia treatment CTP-692 — a deuterium-modified form of D-serine — demonstrated safety and tolerability in a phase 1 trial, said Concert Pharma. (Seeking Alpha)
Nationally representative survey data suggested that over half of people who reported misusing prescription opioids were also binge drinkers. (American Journal of Preventive Medicine)
Did the FDA overlook red flags during the approval process for esketamine (Spravato)? (Kaiser Health News)
Combination treatment pairing psychotherapy and pharmacological treatment was superior to pharmacological treatment alone for PTSD symptoms, according to a meta-analysis. (JAMA Psychiatry)
Ironshore Pharma’s ADHD medication Jornay PM (methylphenidate HCl) extended-release capsules CII, the first ADHD medication dosed in the evening, is now available.
Women who are survivors of intimate partner violence had over 2.6-fold higher odds of having some form of mental illness. (British Journal of Psychiatry)
A group of researchers at the University of New Mexico are trying their hand at an Alzheimer’s vaccine. (CBS News)